Efficacy and safety of post-discharge oral nutritional supplements for patients with gastric cancer undergoing gastrectomy: a meta-analysis of randomized controlled trials.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
586 patients (804 in ONS group versus 782 in control group) were included for meta-analysis.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] ONS was significantly effective and safe in improving postoperative weight loss for patients with gastric cancer undergoing gastrectomy. [SYSTEMATIC REVIEW REGISTRATION] Identifier, CRD42023414678, https://www.crd.york.ac.uk/PROSPERO/.
[OBJECTIVES] To report the first and largest systematic review and meta-analysis of randomized controlled trials (RCT) to evaluated the efficacy and safety of post-discharge oral nutritional supplemen
- RR 1.11
- 연구 설계 systematic review
APA
Liang Q, Wang S, et al. (2024). Efficacy and safety of post-discharge oral nutritional supplements for patients with gastric cancer undergoing gastrectomy: a meta-analysis of randomized controlled trials.. Frontiers in nutrition, 11, 1488054. https://doi.org/10.3389/fnut.2024.1488054
MLA
Liang Q, et al.. "Efficacy and safety of post-discharge oral nutritional supplements for patients with gastric cancer undergoing gastrectomy: a meta-analysis of randomized controlled trials.." Frontiers in nutrition, vol. 11, 2024, pp. 1488054.
PMID
39877540 ↗
Abstract 한글 요약
[OBJECTIVES] To report the first and largest systematic review and meta-analysis of randomized controlled trials (RCT) to evaluated the efficacy and safety of post-discharge oral nutritional supplements (ONS) for patients with gastric cancer undergoing gastrectomy.
[DESIGN] Systematic review and meta-analysis.
[ELIGIBILITY CRITERIA FOR SELECTING STUDIES] RCT which evaluated the efficacy and/or safety of post-discharge ONS for patients with gastric cancer undergoing gastrectomy.
[DATA SOURCES] We conducted a systematic literature retrieval via PubMed, Embase, Web of Science, and Cochrane until April, 2023 for relevant RCTs.
[DATA ANALYSIS] Outcomes of meta-analysis included absolute change of body weight, % change of body weight, absolute change of body composition, absolute change of laboratory parameters and adverse events. All the relevant data were analyzed by Review Manager 5.4.1 and Stata 15.1.
[RESULTS] 5 RCTs including 1,586 patients (804 in ONS group versus 782 in control group) were included for meta-analysis. The two groups were comparable in age, gender (male), weight at baseline, BMI at baseline, albumin at baseline, and hemoglobin at baseline. Meta-analysis revealed a significant lower absolute body weight loss (WMD: 0.75; 95% CI: 0.11, 1.40; = 0.02) and % body weight loss (WMD: 1.15; 95% CI: 0.20, 2.11; = 0.02) in the ONS group compared with the control (regular diet/dietary advice) group. Moreover, this study did not observe a significant difference between the two groups for adverse events rate (RR: 1.11; 95% CI: 0.81, 1.53; = 0.52).
[CONCLUSION] ONS was significantly effective and safe in improving postoperative weight loss for patients with gastric cancer undergoing gastrectomy.
[SYSTEMATIC REVIEW REGISTRATION] Identifier, CRD42023414678, https://www.crd.york.ac.uk/PROSPERO/.
[DESIGN] Systematic review and meta-analysis.
[ELIGIBILITY CRITERIA FOR SELECTING STUDIES] RCT which evaluated the efficacy and/or safety of post-discharge ONS for patients with gastric cancer undergoing gastrectomy.
[DATA SOURCES] We conducted a systematic literature retrieval via PubMed, Embase, Web of Science, and Cochrane until April, 2023 for relevant RCTs.
[DATA ANALYSIS] Outcomes of meta-analysis included absolute change of body weight, % change of body weight, absolute change of body composition, absolute change of laboratory parameters and adverse events. All the relevant data were analyzed by Review Manager 5.4.1 and Stata 15.1.
[RESULTS] 5 RCTs including 1,586 patients (804 in ONS group versus 782 in control group) were included for meta-analysis. The two groups were comparable in age, gender (male), weight at baseline, BMI at baseline, albumin at baseline, and hemoglobin at baseline. Meta-analysis revealed a significant lower absolute body weight loss (WMD: 0.75; 95% CI: 0.11, 1.40; = 0.02) and % body weight loss (WMD: 1.15; 95% CI: 0.20, 2.11; = 0.02) in the ONS group compared with the control (regular diet/dietary advice) group. Moreover, this study did not observe a significant difference between the two groups for adverse events rate (RR: 1.11; 95% CI: 0.81, 1.53; = 0.52).
[CONCLUSION] ONS was significantly effective and safe in improving postoperative weight loss for patients with gastric cancer undergoing gastrectomy.
[SYSTEMATIC REVIEW REGISTRATION] Identifier, CRD42023414678, https://www.crd.york.ac.uk/PROSPERO/.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Pulmonary macrophage-targeted RNAi and mRNA co-delivery via SORT lipid nanoparticles enhances immunotherapy in lung cancer.
- Dioscin suppresses tumorigenesis and overcomes radioresistance by promoting ubiquitination-mediated degradation of Mcl-1.
- DC-STAMP activates the PI3K/AKT/mTOR signaling pathway to regulate PANoptosis in acute myeloid leukemia.
- UFMylation deficiency in hepatocytes activates the KEAP1-NRF2 pathway and contributes to hepatocarcinogenesis.
- Diagnostic importance of serum markers in lung cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Infection Following Implant-based Breast Reconstruction: Lessons from the Five Consecutive Patients.
- Pathological Complete Response after Robot-Assisted Pulmonary Resection Following CDK4/6 Inhibitor-Combined Endocrine Therapy for Endobronchial Oligometastatic Breast Cancer: A Case Report.
- Metastatic Pancreatic Adenocarcinoma with Germline BLM and Somatic ATM Mutations: A Case Report and Review of DNA Damage Response.